Coronavirus Spike Glycoprotein (CoV S) Peptide
CoV S
适用: Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2)
宿主: 合成
InhA
3 images
(3 references)Quick Overview for Coronavirus Spike Glycoprotein (CoV S) Peptide (ABIN6952488)
抗原
Coronavirus Spike Glycoprotein (CoV S)
宿主
Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2)
资源
合成
应用范围
Inhibition Assay (InhA)
-
-
序列
- SLDQINVTFL DLEYEMKKLE EAIKKLEESY IDLKEL
-
产品特性
- EK1 / Pan-HCoV S Inhibitor
-
纯度
- ≥ 95 %
-
组件
- Each vial contains 100 μg of NET peptide.
-
-
Coronavirus Spike Glycoprotein (CoV S) peptide (Cy5)
CoV S 适用: Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2) 宿主: 合成 InhA
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Powder
-
储存条件
- RT,4 °C,-20 °C
-
储存方法
- Up to 6 months in lyophilized form at 0-5°C. For best results, rehydrate just before use. After rehydration, keep solution at -20°C for up to 3 months. Aliquot before freezing to avoid repeated freeze-thaw cycles.
-
-
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." in: Cellular & molecular immunology, (2020) (PubMed).
: "Drug treatment options for the 2019-new coronavirus (2019-nCoV)." in: Bioscience trends, Vol. 14, Issue 1, pp. 69-71, (2020) (PubMed).
: "A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike." in: Science advances, Vol. 5, Issue 4, pp. eaav4580, (2019) (PubMed).
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." in: Cellular & molecular immunology, (2020) (PubMed).
-
- Coronavirus Spike Glycoprotein (CoV S)
-
物质类
- Viral Protein
-
分子量
- 4332
抗原
-
You are here:
